100 related articles for article (PubMed ID: 22415480)
1. Atypical ezrin localization as a marker of locally advanced breast cancer.
Arslan AA; Silvera D; Arju R; Giashuddin S; Belitskaya-Levy I; Formenti SC; Schneider RJ
Breast Cancer Res Treat; 2012 Aug; 134(3):981-8. PubMed ID: 22415480
[TBL] [Abstract][Full Text] [Related]
2. Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas.
Sarrió D; Rodríguez-Pinilla SM; Dotor A; Calero F; Hardisson D; Palacios J
Breast Cancer Res Treat; 2006 Jul; 98(1):71-9. PubMed ID: 16538541
[TBL] [Abstract][Full Text] [Related]
3. [Expression of Ezrin and E-cadherin in invasive ductal breast cancer and their correlations to lymphatic metastasis].
Li Q; Wu MF; Song AP; Wei JC; Xu G; Lu YP; Ma D
Ai Zheng; 2006 Mar; 25(3):363-6. PubMed ID: 16536996
[TBL] [Abstract][Full Text] [Related]
4. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
5. Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer.
Elzagheid A; Korkeila E; Bendardaf R; Buhmeida A; Heikkilä S; Vaheri A; Syrjänen K; Pyrhönen S; Carpén O
Hum Pathol; 2008 Dec; 39(12):1737-43. PubMed ID: 18701134
[TBL] [Abstract][Full Text] [Related]
6. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma.
Abner AL; Collins L; Peiro G; Recht A; Come S; Shulman LN; Silver B; Nixon A; Harris JR; Schnitt SJ; Connolly JL
Cancer; 1998 Dec; 83(12):2502-8. PubMed ID: 9874455
[TBL] [Abstract][Full Text] [Related]
7. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
8. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
[TBL] [Abstract][Full Text] [Related]
9. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients.
Kwon Y; Ro J; Kang HS; Kim SK; Hong EK; Khang SK; Gong G; Ro JY
Oncol Rep; 2011 Apr; 25(4):1063-71. PubMed ID: 21258771
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of ezrin in cutaneous basal and squamous cell carcinomas.
Abdou AG; Maraee AH; El-Sayed EM; Elnaidany NF
Ann Diagn Pathol; 2011 Dec; 15(6):394-401. PubMed ID: 21849257
[TBL] [Abstract][Full Text] [Related]
12. Expression and clinical significance of ezrin in non--small-cell lung cancer.
Zhang XQ; Chen GP; Wu T; Yan JP; Zhou JY
Clin Lung Cancer; 2012 May; 13(3):196-204. PubMed ID: 22137559
[TBL] [Abstract][Full Text] [Related]
13. Breast carcinoma grading, estimation of tumor size, axillary lymph node status, staging, and nottingham prognostic index scoring on mastectomy specimens.
Ahmad Z; Khurshid A; Qureshi A; Idress R; Asghar N; Kayani N
Indian J Pathol Microbiol; 2009; 52(4):477-81. PubMed ID: 19805950
[TBL] [Abstract][Full Text] [Related]
14. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data.
Costa SD; Loibl S; Kaufmann M; Zahm DM; Hilfrich J; Huober J; Eidtmann H; du Bois A; Blohmer JU; Ataseven B; Weiss E; Tesch H; Gerber B; Baumann KH; Thomssen C; Breitbach GP; Ibishi S; Jackisch C; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Jan; 28(1):83-91. PubMed ID: 19901111
[TBL] [Abstract][Full Text] [Related]
16. E-cadherin expression in invasive breast cancer.
Suciu C; Cîmpean AM; Mureşan AM; Izvernariu D; Raica M
Rom J Morphol Embryol; 2008; 49(4):517-23. PubMed ID: 19050801
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
Rudland PS; Platt-Higgins A; El-Tanani M; De Silva Rudland S; Barraclough R; Winstanley JH; Howitt R; West CR
Cancer Res; 2002 Jun; 62(12):3417-27. PubMed ID: 12067984
[TBL] [Abstract][Full Text] [Related]
18. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of Ezrin and CD44 co‑expression in breast cancer.
Ma L; Jiang T
Oncol Rep; 2013 Oct; 30(4):1899-905. PubMed ID: 23900701
[TBL] [Abstract][Full Text] [Related]
20. [Relationship of ezrin protein expression to the carcinogenesis and prognosis of infitrating breast ductal carcinoma].
Ma L; Zhang XH; Xing LX; Li YH; Wang XL; Wang YJ
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):279-83. PubMed ID: 18788632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
